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Abstract 
Background: No curative therapy for mitochondrial disease (MD) exists, prioritizing supportive treatment for 
symptom relief. In animal and cell models ketones decrease oxidative stress, increase antioxidants and scavenge free 
radicals, putting ketogenic diets (KDs) on the list of management options for MD. Furthermore, KDs are well-known, 
safe and effective treatments for epilepsy, a frequent symptom of MD. This systematic review evaluates efficacy and 
safety of KD for MD.
Methods: We searched Pubmed, Cochrane, Embase and Cinahl (November 2020) with search terms linked to MD 
and KD. From the identified records, we excluded studies on Pyruvate Dehydrogenase Complex deficiency. From 
these eligible reports, cases without a genetically confirmed diagnosis and cases without sufficient data on KD and 
clinical course were excluded. The remaining studies were included in the qualitative analysis.
Results: Only 20 cases (14 pediatric) from the 694 papers identified met the inclusion criteria (one controlled trial 
(n = 5), 15 case reports). KD led to seizure control in 7 out of 8 cases and improved muscular symptoms in 3 of 10 
individuals. In 4 of 20 cases KD reversed the clinical phenotype (e.g. cardiomyopathy, movement disorder). In 5 adults 
with mitochondrial DNA deletion(s) related myopathy rhabdomyolysis led to cessation of KD. Three individuals with 
POLG mutations died while being on KD, however, their survival was not different compared to individuals with POLG 
mutations without KD.
Conclusion: Data on efficacy and safety of KD for MD is too scarce for general recommendations. KD should be 
considered in individuals with MD and therapy refractory epilepsy, while KD is contraindicated in mitochondrial DNA 
deletion(s) related myopathy. When considering KD for MD the high rate of adverse effects should be taken into 
account, but also spectacular improvements in individual cases. KD is a highly individual management option in this 
fragile patient group and requires an experienced team. To increase knowledge on this—individually—promising 
management option more (prospective) studies using adequate outcome measures are crucial.
Keywords: Epilepsy, Complex I, Treatment, Management, Mitochondrial myopathy, OXPHOS, Mitochondrial DNA 
deletion, Adverse event, Modified Atkins diet, High fat diet
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Introduction
Mitochondrial diseases (MDs) are a heterogenous group 
of inborn metabolic diseases caused by defects in the 
genes encoding mitochondrial proteins that are required 
for ATP production from oxidation of substrates via the 
tricarboxylic acid cycle and the oxidative phosphoryla-
tion (OXPHOS). Underlying pathogenic variants can be 
found in nuclear or mitochondrial DNA (mtDNA) [1, 2]. 
Currently more than 295 different disorders are known 
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[2]. Virtual all the extremely heterogeneous symptoms 
can occur with onset at all ages, but typically tissues with 
high energy requirements like skeletal/heart muscle and 
brain are mainly affected. Currently no curative treat-
ment is available, making the supportive management for 
symptom relief priority.
Given the key role of mitochondria in energy metabo-
lism and the importance of vitamins and co-factors for 
proper mitochondrial function, nutritional interventions 
are an integral component of daily management [3–7]. 
Moreover, nutritional interventions focusing on nutri-
tional status or gastro-intestinal complaints have been 
shown effective [3, 4].
A ketogenic diet (KD) is a low-carbohydrate high-
fat diet that shifts metabolism towards β-oxidation and 
ketone body production. Three kind of KDs are defined. 
The classic KD uses grams of fat: grams of carbohydrate 
plus protein-ratio (e.g. 4:1 or 3:1) in every meal. Fat can 
be (mainly) given as medium-chain triglyceride (MCT), 
this subtype is called MCT-KD. As MCT-fats are con-
verted easier into ketones than longer chain fatty acids, 
ketosis can be achieved more easily and more carbohy-
drates can be consumed. In contrast, the modified Atkins 
diet (MAD) only restricts carbohydrates (10–20  g per 
day) without restricting the amount of fat and protein 
[8–10].
KDs have been proven successful in the treatment of 
intractable epilepsy and are generally well tolerated and 
safe [9, 11, 12]. It is thought that KDs exert their positive 
effect (among others) via stimulation of mitochondrial 
biogenesis, improvement of mitochondrial function and 
decrease of oxidative stress [13–16] and therefore have 
been implemented in some cases with MD and epilepsy 
[12, 17]. There are also studies suggesting a potential ben-
eficial effect of KD in MD, besides reducing seizures [14, 
18]. However, this was mainly studied in patient derived 
fibroblasts and animal models [8, 14, 19–23]. Of note, 
while it was previously assumed that the liver provides 
ketone bodies to the brain, astrocytes itself have shown 
to be ketogenic cells. This astrocyte ketogenesis might 
control the survival/death decision of neural cells at least 
twofold. By scavenging non-esterified fatty acids the 
ketogenic pathway could prevent the detrimental actions 
of these metabolites and their derivatives (e.g. cera-
mide) on brain structure and function. Further, by acting 
directly as pro-survival metabolites, the ketone bodies 
may preserve neuronal synaptic function and structural 
stability [24].
When a diet provides only small amounts of glucose, 
hormones as glucagon inhibit glycolysis and stimulate 
ketogenesis. These ketone bodies can only be produced 
in the liver and in astrocytes, and provide the mitochon-
drial OXPHOS with a substrate for energy production. 
The fatty acid pathway provides 5.7 times more flavin 
adenine dinucleotide (FADH2) than the glycose pathway 
and therefore fat has a potential benefit over carbohy-
drates as an energy substrate in human complex 1 defi-
ciency [25]. However nicotinamide-adenine-dinucleotide 
(NADH) is still formed from all substrates and complex 1 
is never completely bypassed (Fig. 1).
Pyruvate dehydrogenase complex (PDHC) deficiency 
hampers the conversion of pyruvate to acetyl-CoA and 
KDs are the pathomechanism based therapy as ketones, 
converted to acetyl-CoA, bypass the PDHC [26]. Pyru-
vate Carboxylase deficiency is a contraindication for KD 
as gluconeogenesis is impaired and affected individuals 
depend on nutritional glucose.
Taken together, KDs are an interesting management 
option for MD that needs further evaluation. We here 
perform a systematic literature review to assess efficacy 
and safety of KD for MD.
Methods
Search strategy
This systematic review was conducted according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) guidelines [27]. We identified 
relevant studies using medical subject headings (MeSH) 
and text words related to KD and MD (see Additional 
file 1). The databases searched were: Pubmed, Cochrane, 
Embase and Cinahl (November 2020) without any search 
limits. The search strategy for Pubmed was gener-
ated together with a specialist librarian and accordingly 
amended for the other databases.
Study selection
Two authors (HZ, AvW) independently screened and 
selected the papers using Rayyan® [28]. Eligibility criteria 
were: cases with MD using a KD and English language. 
The same authors reviewed full-texts of these selected 
papers independently, according to exclusion criteria. 
Disagreements were resolved by consensus and discus-
sion with a third author (SBW). Exclusion criteria were: 
(i) cases without genetically proven MD [1, 2], (ii) cases 
with PDHC-deficiency, (iii) cases not on KD or without 
details of the KD composition and (iv) cases without 
data of effect on clinical phenotype before and under 
treatment.
KD was defined as any dietary manipulation of fat, 
carbohydrate and protein aiming to achieve ketosis and 
included the ‘classic’ KD, MCT-KD or MAD [8–10]. High 
fat diets including the low glycaemic index diet are not 
likely to achieve ketosis and therefore cases treated with 
these diets were excluded.
Reference lists were reviewed for additional 
publications.
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Outcome measures
The primary outcome was the effect of KD on clinical 
phenotypes (epilepsy, muscle involvement, tonus dys-
regulation (muscular hyper- or hypotonia), movement 
disorders, developmental delay and intellectual disabil-
ity (DD/ID), other individual signs and symptoms) and 
the occurrence of adverse events (AEs). The second-
ary outcome was defined as the effect of KD on MRI 
findings and laboratory values (e.g. lactic acidosis, liver 
function test).
Data extraction and quality appraisal
Two authors (HZ, AvW) extracted data and checked 
the data for completeness. A third author (SBW) 
checked all articles again to ensure correct interpreta-
tion of data. Discrepancies were resolved through dis-
cussion and consensus.
We used The Oxford Levels of Evidence 2 [29] scoring 
to assess study quality as well as the The Risk Of Bias In 
Non-randomized Studies—of Interventions (ROBINS-
I) assessment tool [30]. No studies were suitable for 
pooling of the results and therefore a narrative analysis 
is presented.
Results
The search strategy yielded 1149 abstracts (PRISMA 
flowchart, Fig.  2 [31]) of which 17 papers reporting 20 
cases were included in the detailed analysis. All data are 
summarized in Table  1 and Fig.  3. Of note, (multi)vita-
mins and other food supplements were reported in many 
of the included cases (see Table 1 for details). With excep-
tion of one case (TPK1 [32]) clinically not responding to 
thiamine supplementations, none of the reported vita-
mins or co-factors were pathomechanism based treat-
ment options and therefore were not taken into account 
in our analysis.
Case characteristics
Of the 20 cases (12 female), 16 had a nuclear DNA 
and 4 a mtDNA related mutation. Of note 3 of the 
nuclear variants (TWNK) lead to multiple mtDNA 
deletions. The ages at start of KD ranged between 
0 and 62  years (1 neonate (aged 7  days), 2 infants (9 
and 10  months), 11 children (1.3–16  years), 6 adults 
(aged 22–62  years)). Eight individuals (8/20), were 
described as having epilepsy. In 10/20 individuals mus-
cle involvement (cardiomyopathy, muscle weakness, 
exercise intolerance, ptosis) was reported, 7/20 were 
Fig. 1 Metabolic pathways of carbohydrates, fat and ketone bodies in energy metabolism. ATP adenosine triphosphate, C respiratory chain 
complex, PDHC pyruvate dehydrogenase complex, PC pyruvate carboxylase, TCA Cycle Tricarboxylic acid cycle also called citric acid cycle
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described having tonus dysregulation, and for 5/20 
cases movement disorder(s) (ataxia, dystonia) were 
reported. In 10/20 cases DD/ID was reported. Other 
reported symptoms were visual problems, respiratory 
distress, headaches/migraine, failure to thrive, feed-
ing problems, gastro-intestinal problems, alopecia and 
hearing loss.
Study quality
The general study quality was low, with 15 case reports 
(category 4) and one controlled trial with 5 adult par-
ticipants (category 3b). The risk of bias in the trial was 
scored as low.
Interventions
Eleven cases followed a classical KD, 8 cases a MAD. For 
one case the composition of the KD was not detailed, 
however, this case was included as achievement of keto-
sis was documented. For a total of 14 cases achieve-
ment of ketosis was reported. The total diet duration of 
all 20 cases together was > 22 patient years, the median 
diet duration was 4 months (range 4 days -9 years). The 
main reasons for discontinuation of the diet (n = 12) were 
death (n = 3) [33–35] and other AEs (n = 7) [36–39]. In 
one case the daily constraints [40] and in one case the 
child’s craving for carbohydrates and lack of improve-
ment of hearing [41] lead to cessation after 2  years and 
4 months, respectively.
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Fig. 2 PRISMA flowchart. This figure detailing the search strategy
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Primary outcomes
Effect of KD on epilepsy
In 7/8 cases with uncontrolled epilepsy seizure control 
was achieved with KD (5 seizure free, 1 reduction of sei-
zures and 1 “stabilisation” of status epilepticus). In 4 of 
these cases the effect was only temporary (lasting a few 
weeks to 7 months). In one case no positive effect of the 
KD on epilepsy was reported, and the KD was stopped 
after 5 days due to metabolic acidosis.
Effect of KD on other clinical signs and symptoms
Skeletal and  heart muscle In 3/10 cases with muscle 
involvement KD had a positive effect. This was the return 
of bladder and bowel control, and the ability to walk with 
assistance [33], and the complete resolve of chronic pro-
gressive ophthalmoplegia (CPEO) and ptosis [40]. In the 
third case, the 3-year-old individual regained walking 
abilities with improved lower limb muscle strength after 
one year of KD and normalisation of septum thickness of 
hypertrophic cardiomyopathy after 3  years of KD. This 
effect was sustained at the last follow up at age 11 years 
(total 8 years of KD) [42]. A negative effect was observed 
in 6/10 individuals. Five of these six individuals experi-
enced rhabdomyolysis, headache and fatigue leading to 
cessation of KD after 4 to 11  days [38] and in one case 
progressive muscular hypotonia with swallowing difficul-
ties was reported going along with a weight loss below the 
 3rd percentile [37].
Tonus dysregulation Tonus dysregulation was reported 
to improve in 3/7 cases, while in one case progressive 
muscular hypotonia was only reported after the KD was 
started [37]. In all 3 cases head control improved [32, 43, 
44] and one case additionally showed improved stability 
of truncal tone enabling him to stand with support and to 
sit independently [32].
Movement disorder In one case the paroxysmal ophis-
thotonic dystonia completely resolved for more than 
5 years of follow-up [45]. In one individual the ataxia did 
not improve [46], in the other 3 cases no further details 
were provided [33, 34, 40].
Developmental delay/Intellectual disability In 3/10 
cases with DD/ID a positive effect of KD was reported 
(e.g. increased verbal response and abilities, social inter-
action, improved memory) however no data of formal 
psychological or developmental testing were presented 
[32, 33, 44]. The other publications did not provide fur-
ther details.
Other An improved oral food intake [32], improved 
weight gain and growth [42] and hair growth in an indi-
vidual with alopecia [41] were reported in one case each.
Treatment‑withdrawal effect In 3 cases a treatment 
withdrawal effect was demonstrated. In the case where KD 
had resulted in hair growth, this was lost again 6 months 
after cessation of KD [41]. In the individual where KD led 
to dissapearance of the dystonic-opisthotonic episodes 
within 5 days for 5 months, these reoccured within a few 
days when the KD was stopped, and dissapeared again 
4  weeks after reintroducing KD [45]. In the case where 
CPEO and ptosis resolved within days and remained 
absent for 2  years on KD, the ptosis partially reoccured 
upon “relaxation" of the diet [40].
Adverse events
In 13/20 individuals AEs were reported (Table 1). In one 
study [38] all 5 adult participants with mitochondrial 
myopathy (2 mtDNA single deletion, 3 TWNK/multi-
ple mtDNA deletions) stopped MAD within 4–11  days 
because of rhabdomyolysis, headache and tiredness.
Three individuals, all with POLG-related Alpers syn-
drome, died during KD (at the ages of 46  months [34], 
66  months [33] and 16  years [35]) of respiratory failure 
(n = 2) or paralytic bowel obstruction (n = 1). This was 
3 months (n = 2) [34, 35] and 35 months [33] respectively, 
after presentation.
Other AEs that lead to immediate cessation of the KD 
were severe lethargy, which occurred after 5  months of 
KD in one case [39] and lactic acidosis (after 5  days of 
KD) in one other case [36]. Of note, two individuals in 
two reports remained on KD despite AEs. In one case 
because of successful seizure reduction despite a sud-
den deterioration of visual acuity, ptosis and general 
weakness after 6 months of KD [46] and in one case the 
resolve of the movement disorder outweighed the wors-
ening seen on MRI [45]. In one individual [37] who suf-
fered from weight loss, regression and hypotonia the KD 
was continued for 3.3 months and then weaned to a more 
conventional feeding regime.
Secondary outcomes
From the 12 cases with reported MRI abnormalities for 
only 2 cases MRI details were provided after KD initia-
tion. In one case a resumed myelination during KD was 
observed [44], while in the second the MRI worsened 
[45]. Interestingly in the latter case, the movement disor-
der had completely resolved and the patient was reported 
to develop age-adequately. In 7 cases lactic acidosis was 
reported which normalised in one [39], worsened in 
one [36] and did not change in 2 cases [37, 40]. For the 
remaining 3 cases no details were reported [42, 43, 46]. 
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Two individuals with POLG mutations had mildly ele-
vated liver function tests before KD initiation [33, 34]. 
In one case these remained elevated [33], in the other 
case no details were provided [34]. In one individual a 
transient, four day long, increase in liver function tests 
occurred [35].
Discussion
Despite identifying 694 studies using our search strat-
egy, only 20 cases (one controlled trial (n = 5) and 15 
case reports) were of sufficient quality for detailed anal-
ysis. These data are too scarce to draw firm conclusions 
regarding efficacy and safety of KD. Future reports on KD 
for MDs must present a minimum of “common data ele-
ments” (in line with the data shown in Table 1) describ-
ing the composition of KD as well as the clinical effect 
including adverse events.
KD is effective for seizure control in MD
KD was highly effective and led to seizure control of 
therapy refractory seizures in 7 of 8 MD cases, at least 
temporarily. KD was stopped only after 5 days in the 8th 
case and it remains elusive if adaptation of the KD would 
have overcome the occurring lactic acidosis and would 
have led to seizure control. The number of cases does not 
allow comparing with the efficacy of KD for intractable 
seizures of other causes (up to 55%/25% becoming sei-
zure free on 4:1 classical KD/MAD [9]).
KD might be effective for the treatment of other 
signs and symptoms of MD in individual cases, 
but is contraindicated in mtDNA deletion(s) related 
myopathy
In 12/20 cases KD was initiated for other indications than 
epilepsy. In 5 adults with mitochondrial myopathy KD 
Fig. 3 Summary of positive and negative effects of ketogenic diet in 20 cases with genetically proven mitochondrial disease. This figure visualises 
the negative effects and adverse events on the left and the positive effects (on the right) of ketogenic diet in 20 cases with genetically proven 
mitochondrial disease. *temporary effect **cases with reported treatment-withdrawal effect. B/B bladder and bowel, CPEO chronic progressive 
external ophthalmoplegia, del deletions, HC head control, mult multiple deletions in mitochondrial DNA, MRI magnetic resonance imaging, mtDNA 
mitochondrial DNA, SLE stroke like episodes, SM skeletal muscle, TD tonus dysregulation
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was stopped due to AEs in all participants [38]. However, 
a potential long term benefit cannot be excluded, as the 
authors report a slight improvement on muscle strength 
and in 6-min walking test in three of four patients after 
2.5 years of follow up after cessation of KD.
In the remaining 7 pediatric cases, 5 improved clini-
cally [32, 40–42, 45], mainly concerning muscle symp-
toms. Especially the well reported treatment-withdrawal 
effect in three cases (start/stop hair growth, resolving/
reoccurring ptosis or movement disorder) illustrates the 
potential for KD in individual management of MD. Of 
note, in one case hypertrophic cardiomyopathy was com-
pletely resolved on KD and sustained without any addi-
tional medication [42]. The authors discuss that ketone 
bodies may have modulated cardiac metabolism. This is 
in line with the data suggesting that in heart failure due 
to metabolic dysfunction fatty acids allow for sufficient 
energy production while carbohydrates may contribute 
to declining contractile function. A role for ketones both 
in signalling as well as an energy source is suspected to 
underlie this [47].
Safety aspects of KD for MD
AEs occurred 65% of MD cases during KD. This percent-
age is comparable with studies on KD for PDHC defi-
ciency (13/19 = 68%) [26] or epilepsy with mitochondrial 
dysfunction (22/34 = 65%) [12, 17]. AEs of KD reported 
in literature for refractory epilepsy are mainly gastroin-
testinal complaints rarely leading to discontinuing of the 
diet, but also lethargy and acidosis have been reported [9, 
11].
The 3 children with MD that died (aged 
66–192  months) while being on KD all had POLG‑
related Alpers disease, an early lethal disorder with a 
median age at death of 16 (range 1–181) months [48]. 
Hence, their age of death is comparable. Moreover, the 
median survival after presentation is reported to be 5 
(0.5–181) months without KD [48], and was 3 (n = 2) and 
35 months, in the cases with KD reviewed here.
Hence, from these limited data it seems unlikely that 
KD negatively influenced mortality, but is in line with the 
natural disease course of childhood onset MD.
Practical recommendations
The current guidelines on KD list complex I deficiency 
as a condition for which KD has been shown reportedly 
more beneficial when compared to the average response 
to KD in refractory epilepsy [11, 12, 49] in general. This 
pathomechanism approach assumes that fatty acids com-
pared to carbohydrates produce more FADH that can 
enter complex II [12, 18, 49, 50] and hence allows (par-
tial) bypassing of complex I. However, as outlined in the 
introduction (Fig. 1), NADH is still formed from all sub-
strates and complex I is never completely bypassed.
Our study did solely include cases with known genetic 
background as increasing knowledge from next gen-
eration studies shows that complex I deficiency cannot 
only be seen in MD but also in other genetic diseases 
especially if measured in muscle specimen of patients 
with terminal disease [51]. Hence, there is insufficient 
evidence that KD is more beneficial in mitochondrial 
complex I related disease than in other MD [11] or even 
other therapy refractory epilepsies. However, from our 
results we conclude that KD should be considered in 
MD patients with therapy resistant epilepsy.
Given the risk of AEs KD should be initiated by a 
team experienced with both MD and KD. Especially in 
the first weeks clinical and laboratory controls should 
be frequent (in line with the general guideline on KD). 
From our data we cannot conclude after which dura-
tion the efficacy can be judged and we therefore recom-
mend a three months trial of KD, in analogy to KD for 
intractable epilepsy [52]. Whether classic KD or MAD 
is superior is unknown and an individual top-down 
(start KD 4:1) or bottom up approach (start with MAD) 
should be weighed and discussed with patient and/or 
parents.
An appraisal for high fat diets
In this context, we would like to mention the high fat 
diets. The beneficial effects of KD for MDs are probably 
not only based on ketogenesis and energy expenditure 
from ketone bodies [22, 53]. Two studies that did not met 
our inclusion criteria, reporting 4 MD cases with com-
plex I deficiency in muscle without a genetic diagnosis, 
showed improved maximal workload and muscle force 
under high fat diet [54, 55]. Another n = 1 trial reported 
a high fat diet improving the endurance in a bicycle test 
when compared to a high carbohydrate diet in one adult 
(TMEM126B) [50].
There is further interesting evidence to encourage 
human studies on high fat diets for MD First, supple-
menting of complex I deficient human fibroblast cell 
lines with palmitate resulted in protection from cell 
death caused by glucose withdrawal presumably based 
on fatty acid induced stimulation of mitochondrial bio-
genesis. Second, the study of a mouse model of Harlequin 
complex I deficient mice established that a high fat diet 
slowed down disease progression regarding major neuro-
degenerative symptoms and cerebellar atrophy [56].
More studies on high fat diet in humans reporting the 
aforementioned common data elements are necessary to 
draw conclusions. However, it also has to be considered 
that a high-fat diet could downregulate genes involved in 
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the mitochondrial respiratory chain, and could thereby 
worsen the mitochondrial dysfunction [57].
Conclusion
Data on efficacy and safety of KD for MD is too scarce 
for general recommendations. KD should be consid-
ered in individuals with MD and therapy refractory 
epilepsy, while mtDNA deletion(s) related myopathy 
is a contraindication (as well as Pyruvate Carboxylase 
deficiency). KD is a highly individual management 
option in this fragile patient group and requires an 
experienced team. To increase knowledge on this—
individually—promising management option more 
(prospective) high quality studies using adequate out-
come measures are crucial.
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